Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.

Cancer medicine 20150701

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.

Proceedings of the National Academy of Sciences of the United States of America 20150317

Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects.

International journal of molecular sciences 20150101

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.

Clinical cancer research : an official journal of the American Association for Cancer Research 20141115

Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.

Journal of medicinal chemistry 20141009

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.

Cancer letters 20140901

ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.

Clinical advances in hematology & oncology : H&O 20140701

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.

Journal of medicinal chemistry 20140612

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Cancer discovery 20140601

Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.

Nature 20140410

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.

Journal of medicinal chemistry 20140227

Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.

Toxicology and applied pharmacology 20131001

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters 20130801

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.

Journal of medicinal chemistry 20130725

Crizotinib for the treatment of non-small-cell lung cancer.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20130601

Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).

Cancer treatment reviews 20130501

Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors.

Journal of biomolecular screening 20130401

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.

Disease models & mechanisms 20130301

Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.

Drug metabolism and disposition: the biological fate of chemicals 20130201

Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients.

International journal of cancer 20130115

Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.

Current pharmaceutical design 20130101

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.

Oncogene 20121213

Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?

Cancer biology & therapy 20121201

Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report.

Lung cancer (Amsterdam, Netherlands) 20121201

Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.

Oncogene 20121115

Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20121115

Hypogonadism related to crizotinib therapy: implications for patient care.

Cancer 20121101

Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.

Cancer 20121101

Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20121101

ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20121101

Targeted therapy for lung cancer.

Anti-cancer drugs 20121101

The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.

The Journal of biological chemistry 20121026

Crizotinib in ALK-positive lung cancer.

The Lancet. Oncology 20121001

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

The Lancet. Oncology 20121001

Treatment of ALK-positive non-small cell lung cancer.

Archives of pathology & laboratory medicine 20121001

Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.

Journal of medicinal chemistry 20120927

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.

Cancer 20120915

Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120915

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.

Virchows Archiv : an international journal of pathology 20120901

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.

Bioorganic & medicinal chemistry 20120901

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120901

Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?

Clinical cancer research : an official journal of the American Association for Cancer Research 20120901

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120901

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.

Targeted oncology 20120901

[Cavitating nodules in a 40-year-old non-smoking woman: a very particular tumour].

Revue des maladies respiratoires 20120901

Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas.

Annals of oncology : official journal of the European Society for Medical Oncology 20120901

Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.

Cancer science 20120801

ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.

Lung 20120801

Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120801

Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120715

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

Cancer cell 20120710

Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.

British journal of pharmacology 20120701

HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.

Cancer letters 20120701

Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120701

Inhibitors of the anaplastic lymphoma kinase.

Expert opinion on investigational drugs 20120701

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120701

Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors.

Current opinion in oncology 20120701

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.

Nature medicine 20120701

Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.

Molecular cancer therapeutics 20120701

Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.

Expert review of molecular diagnostics 20120701

Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.

Neoplasia (New York, N.Y.) 20120701

A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK.

Biochemical and biophysical research communications 20120629

Targeted therapy for NSCLC: ALK inhibition.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20120601

Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers.

Lung cancer (Amsterdam, Netherlands) 20120601

Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.

Molecular diagnosis & therapy 20120601

Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120601

Development of treatment strategies for advanced neuroblastoma.

International journal of clinical oncology 20120601

Crizotinib in the treatment of non-small-cell lung cancer.

Expert opinion on pharmacotherapy 20120601

ALKoma: a cancer subtype with a shared target.

Cancer discovery 20120601

Novel molecular trends in the management of advanced non-small-cell lung cancer.

Expert review of anticancer therapy 20120601

Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS.

Current oncology (Toronto, Ont.) 20120601

Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line.

Current oncology (Toronto, Ont.) 20120601

Supportive care treatments for toxicities of anti-egfr and other targeted agents.

Current oncology (Toronto, Ont.) 20120601

Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.

Journal of medicinal chemistry 20120524

Targeting ALK in neuroblastoma--preclinical and clinical advancements.

Nature reviews. Clinical oncology 20120515

Promising therapeutic targets in neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120515

ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.

Lung cancer (Amsterdam, Netherlands) 20120501

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.

European journal of cancer (Oxford, England : 1990) 20120501

Treating ALK-positive lung cancer--early successes and future challenges.

Nature reviews. Clinical oncology 20120501

Application of mid-infrared spectroscopy to the development and transfer of a manufacturing process for an active pharmaceutical ingredient.

Applied spectroscopy 20120501

[Which platform to support a personalized lung cancer treatment?].

Bulletin du cancer 20120501

Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer.

The oncologist 20120501

Advances in treatment of lung cancer with targeted therapy.

Archives of pathology & laboratory medicine 20120501

Discovery pharmacokinetic studies in mice using serial microsampling, dried blood spots and microbore LC-MS/MS.

Bioanalysis 20120501

Personalized targeted therapy in advanced non-small cell lung cancer.

Cleveland Clinic journal of medicine 20120501

Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinib.

The American journal of managed care 20120501

Treating Anaplastic Lymphoma Kinase-Positive Lung Cancer in the Weeks After the US Food and Drug Administration Approval of Crizotinib.

Journal of oncology practice 20120501

Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma.

Cellular signalling 20120401

The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation.

Current oncology reports 20120401

The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer.

Expert opinion on therapeutic targets 20120401

Astellas' drug discovery strategy: focus on oncology.

Japanese journal of clinical oncology 20120401

RNA-Seq mapping and detection of gene fusions with a suffix array algorithm.

PLoS computational biology 20120401

ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway.

Expert review of anticancer therapy 20120401

Crizotinib for the treatment of patients with advanced non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998) 20120401

Recent advances in non-small cell lung cancer biology and clinical management.

Discovery medicine 20120401

Redefining clinical trials: the age of personalized medicine.

Cell 20120316

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.

British journal of cancer 20120313

ROS1 rearrangements define a unique molecular class of lung cancers.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120310

Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.

The Journal of pharmacology and experimental therapeutics 20120301

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120301

LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.

Cancer research 20120301

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120301

Present status and problems on molecular targeted therapy of cancer.

Cancer research and treatment : official journal of Korean Cancer Association 20120301

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Science translational medicine 20120208

Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.

Science translational medicine 20120208

Crizotinib (xalkori) for non-small cell lung cancer.

The Medical letter on drugs and therapeutics 20120206

Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.

Journal of cellular and molecular medicine 20120201

Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120201

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.

Molecular cancer therapeutics 20120201

Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.

Molecular cancer therapeutics 20120201

Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.

Expert review of anticancer therapy 20120201

Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis.

Current opinion in genetics & development 20120201

ROS1 gene rearrangement is identified in NSCLC.

Cancer discovery 20120201

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120120

Drug approvals 2011: focus on companion diagnostics.

Journal of the National Cancer Institute 20120118

ALK gene amplified in most inflammatory breast cancers.

Journal of the National Cancer Institute 20120118

Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

Cancer cell 20120117

7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.

Journal of medicinal chemistry 20120112

Challenges ahead for companion diagnostics.

Journal of the National Cancer Institute 20120104

ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.

Lung cancer (Amsterdam, Netherlands) 20120101

More than just an oncogene translocation and a kinase inhibitor: Kevin's story.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120101

Rhus verniciflua stokes against advanced cancer: a perspective from the Korean Integrative Cancer Center.

Journal of biomedicine & biotechnology 20120101

Crizotinib: in locally advanced or metastatic non-small cell lung cancer.

Drugs 20120101

Drug development: portals of discovery.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120101

Evaluating translocation gene fusions by SNP array data.

Cancer informatics 20120101

Ancillary testing in lung cancer diagnosis.

Pulmonary medicine 20120101

Personalized therapy of lung cancer.

Onkologie 20120101

STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.

PloS one 20120101

KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only.

PloS one 20120101

ALK-activating homologous mutations in LTK induce cellular transformation.

PloS one 20120101

A novel classification of lung cancer into molecular subtypes.

PloS one 20120101

Companion diagnostics: changing patient management.

Ecancermedicalscience 20120101

Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma.

Advances in hematology 20120101

Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment.

PloS one 20120101

Novel therapies for aggressive B-cell lymphoma.

Advances in hematology 20120101

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma.

Frontiers in oncology 20120101

ALK Inhibitors, a Pharmaceutical Perspective.

Frontiers in oncology 20120101

A Screening Method for the ALK Fusion Gene in NSCLC.

Frontiers in oncology 20120101

[Will targeted therapies replace chemotherapy?].

Revue medicale de Liege 20120101

Targeted therapies in sarcomas: challenging the challenge.

Sarcoma 20120101

Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents.

ISRN oncology 20120101

[Management of crizotinib, a new individualized treatment].

Bulletin du cancer 20120101

Predictive role of computer simulation in assessing signaling pathways of crizotinib-treated A549 lung cancer cells.

Asian Pacific journal of cancer prevention : APJCP 20120101

Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.

Cancer journal (Sudbury, Mass.) 20120101

EML4-ALK-positive non-small cell lung cancer in a patient treated with azathioprine for ulcerative colitis.

Tumori 20120101

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111220

MET signaling pathway: a rational target for cancer therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111220

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.

The Biochemical journal 20111215

Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.

ACS medicinal chemistry letters 20111208

Role of randomized phase III trials in an era of effective targeted therapies.

Nature reviews. Clinical oncology 20111206

Role of genotyping in non-small cell lung cancer treatment: current status.

Drugs 20111203

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20111201

New strategies for treatment of ALK-rearranged non-small cell lung cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research 20111201

Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.

Chemical biology & drug design 20111201

Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111201

Crizotinib.

Nature reviews. Drug discovery 20111201

Incorporation of crizotinib into the NCCN guidelines.

Journal of the National Comprehensive Cancer Network : JNCCN 20111201

Crizotinib and testing for ALK.

Journal of the National Comprehensive Cancer Network : JNCCN 20111201

Targeted treatment tested as potential cancer cure.

Nature 20111116

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Science translational medicine 20111109

Larger companies dominate cancer companion diagnostic approvals.

Nature biotechnology 20111108

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

Expert review of anticancer therapy 20111101

Proof of principle for crizotinib in anaplastic lymphoma kinase-positive malignancies was achieved in ALK-positive nonclinical models.

Molecular cancer therapeutics 20111101

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20111101

The potential for crizotinib in non-small cell lung cancer: a perspective review.

Therapeutic advances in medical oncology 20111101

Comprehensive analysis of kinase inhibitor selectivity.

Nature biotechnology 20111030

MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111001

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

The Lancet. Oncology 20111001

Hope without hype: EML4-ALK inhibition for treatment of lung cancer.

The Lancet. Oncology 20111001

Emerging importance of ALK in neuroblastoma.

Seminars in cancer biology 20111001

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

Journal of medicinal chemistry 20110922

9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors.

Journal of medicinal chemistry 20110922

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Cancer research 20110915

Anaplastic lymphoma kinase in human cancer.

Journal of molecular endocrinology 20110801

Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110801

Synthesis of an aryloxy oxo pyrimidinone library that displays ALK-selective inhibition.

Bioorganic & medicinal chemistry letters 20110801

Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110801

Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.

Cancer science 20110801

Receptor kinase inhibitors target NSCLC: two antibodies and a small-molecule MET inhibitor.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20110801

Crizotinib: an anaplastic lymphoma kinase inhibitor.

Future oncology (London, England) 20110801

Phase 1 clinical trials for sarcomas: the cutting edge.

Current opinion in oncology 20110701

[Molecular targeted drugs against ALK fusions].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20110701

The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110601

[What choice of first-line treatment?].

Revue de pneumologie clinique 20110601

[What is the best sequence of treatment for patients with EGFR mutations?].

Revue de pneumologie clinique 20110601

[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].

Revue de pneumologie clinique 20110601

ALK-targeted therapy for lung cancer: ready for prime time.

Oncology (Williston Park, N.Y.) 20110601

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110520

Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110515

Virtual screening and further development of novel ALK inhibitors.

Bioorganic & medicinal chemistry 20110515

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

Proceedings of the National Academy of Sciences of the United States of America 20110503

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110501

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities.

Therapeutic advances in medical oncology 20110501

Targeting anaplastic lymphoma kinase in lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.

Journal of medicinal chemistry 20110414

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110401

Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers.

Oncotarget 20110401

Early accelerated approval for highly targeted cancer drugs.

The New England journal of medicine 20110324

NSCLC drug targets acquire new visibility.

Journal of the National Cancer Institute 20110302

Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.

Drug metabolism and disposition: the biological fate of chemicals 20110301

Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703.

Expert opinion on therapeutic targets 20110301

Personalizing therapy with targeted agents in non-small cell lung cancer.

Oncotarget 20110301

New targets in advanced NSCLC: EML4-ALK.

Clinical advances in hematology & oncology : H&O 20110301

Crizotinib in anaplastic large-cell lymphoma.

The New England journal of medicine 20110224